Appreciation of the importance of platelets and coagulation factors in therothrombotic events has led to the widespread use and continuous development of new antithrombotic agents. This field of cardiovascular pharmacology has advanced at a very rapid rate.
Understanding the basic principles of atherothrombosis as well as the pharmacological agents currently available or under clinical development are key to the successful treatment of patients with atherothrombotic manifestations, particularly coronary artery disease.
Clinical Guide to the Use of Antithrombotic Drugs in Coronary Artery Disease presents the work of internationally renowned contributors who examine pharmacological principles, indications for use, and pitfalls of antithrombotic agents most commonly utilized in treating patients with coronary artery disease. They also describe special clinical scenarios which may call for a multi-pharmacological approach or which demonstrate various undesired effects of antithrombotic agents.
Table of Contents
List of Contributors. Foreword. Preface. Color Plates. Section I Basic Concepts of Atherothrombosis. 1. Fundamentals of the Thrombosis Cascade: Interaction Between Platelets and the Coagulation Cascade. 2. Platelet Receptors and Their Role in Atherothrombosis. 3. Laboratory Assessment of Platelet Function and Coagulation. Section II: Antithrombotic drugs. II.A: Oral Antiplatelet Drugs. 4. Cyclooxygenase Inhibition in Atherothrombotic Disease. 5. P2Y12 Receptor Antagonism: From Bench to Bedside. 6. Timing, Dosing and Length of Clopidogrel Therapy. 7. Resistance to Antiplatelet Drugs: Aspirin. 8. Resistance to Antiplatelet Drugs: Clopidogrel. 9. Prasugrel – a Third-Generation Thienopyridine. 10. Direct oral P2Y12 Inhibition: AZD6140 (Ticagrelor). 11. Emerging Oral Antiplatelet Receptor Inhibitors. II.B Intravenous Antiplatelet Drugs. 12. Platelet Glycoprotein IIb/IIIa Receptor Antagonists: Fundamental and Pharmacological Aspects. 13. Platelet Glycoprotein IIb/IIIa Receptor Antagonists: a Guide to Patient Selection and Optimal Use. 14. Cangrelor. II.C Thrombin Inhibitors and Thrombin Generation Inhibitors. 15. Indirect Thrombin Inhibitors: Fundamentals and Guide to Optimal Therapy Using. Unfractionated Heparin and Low-Molecular-Weight Heparins. 16. Direct Thrombin Inhibitors. 17. Fondaparinux in Acute Coronary Syndromes. 18. Tissue Factor Inhibitors. II.D: Fibrinolytic Therapy. 19. Fibrinolytics: Current Indications and Treatment Modalities in the Absence of Mechanical Reperfusion. 20. Fibrinolytics and Percutaneous Coronary Intervention. Section III Special Situations. 21. Role of Facilitated Percutaneous Coronary Intervention in ST-elevation Myocardial Infarction. 22. Antithrombotic Treatment in Vein Graft Interventions. 23. Antiplatelet Therapy in Diabetes Mellitus. 24. Stent Thrombosis in the Era of Drug-Eluting Stents. 25. Bleeding Complications: Anticoagulant and Antiplatelet Therapy Control. 26. Heparin-Induced Thrombocytopenia: Etiopathogenesis, Clinical Presentation, and Management. 27. Antithrombotic Therapies for Patients with Cerebrovascular, Peripheral Arterial, and Coronary Artery Disease. 28. Dual Antiplatelet Strategies in Patients Requiring Vitamin K Antagonists. Appendix. Index.